[Evaluation of endometrium during tamoxifen therapy of breast cancer].
Tamoxifen is one of most common drugs for breast cancer therapy. But its weak estrogenic activity in endometrium can be the source of different abnormalities including even endometrial cancer.


OBJECTIVE
The aim of this clinical trial was to compare ultrasound scan results, hysteroscopy and pathomorphological findings of tamoxifen treated patients with breast cancer who complained of bleeding.


METHODS
Analyzed group consisted of 10 patients treated for abnormal endometrium during breast cancer tamoxifen therapy.


RESULTS
Among 10 examined women 7 presented no pathological changes, there was 1 case of simple benign hypertrophy and 2 cases of endometrial polyps.


CONCLUSIONS
There is no exact correlation between ultrasound scan results and pathomorphological findings in patients treated with tamoxifen for of breast cancer. Transvaginal ultrasound examination is not efficient screening test for endometrial abnormalities during tamoxifen therapy.
Obrebowska
Anna
A
Kliniki Ginekologii Operacyjnej, GPSK AM w Poznaniu.
Sibila-Owczarska
Agnieszka
A
Sajdak
Stefan
S
D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D016889:Endometrial Neoplasms / Q000139:chemically induced / Q000473:pathology; D004717:Endometrium / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000473:pathology*; D005260:Female; D006801:Humans; D008875:Middle Aged; D011127:Polyps / Q000139:chemically induced / Q000473:pathology; D017698:Postmenopause; D013629:Tamoxifen / Q000009:adverse effects*; D013997:Time Factors; D016896:Treatment Outcome; D014463:Ultrasonography
D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen